These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 4310618)

  • 21. A comparison of the effects of angiotensin-converting enzyme inhibitors with bradykinin, angiotensin II and their specific antagonists on concanavalin A-induced proliferation of mouse T-lymphocytes.
    Yeung JH
    Methods Find Exp Clin Pharmacol; 1994 Apr; 16(3):163-72. PubMed ID: 8046949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic treatment with quercetin does not inhibit angiotensin-converting enzyme in vivo or in vitro.
    Neto-Neves EM; Montenegro MF; Dias-Junior CA; Spiller F; Kanashiro A; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):825-9. PubMed ID: 20406213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired angiotensin conversion and bradykinin clearance in experimental canine pulmonary emphysema.
    Stalcup SA; Leuenberger PJ; Lipset JS; Osman MM; Cerreta JM; Mellins RB; Turino GM
    J Clin Invest; 1981 Jan; 67(1):201-9. PubMed ID: 6256412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
    Hayashi N; Yamamoto S; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The angiotensin type II receptor tonically inhibits angiotensin- converting enzyme in AT2 null mutant mice.
    Hunley TE; Tamura M; Stoneking BJ; Nishimura H; Ichiki T; Inagami T; Kon V
    Kidney Int; 2000 Feb; 57(2):570-7. PubMed ID: 10652034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
    Gubert S; Braso MA; Sacristán A; Ortiz JA
    Farmaco; 1990 Jan; 45(1):59-79. PubMed ID: 2186741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide inhibitors of pulmonary angiotensin I converting enzyme.
    Sander GE; West DW; Huggins CG
    Biochim Biophys Acta; 1971 Sep; 242(3):662-7. PubMed ID: 4334407
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of angiotensin II and bradykinin on insulin-stimulated tyrosine kinase activity of insulin receptor.
    Baba T; Drenckhan M; Neugebauer S; Klein H
    Diabetologia; 1998 Jun; 41(6):741-2. PubMed ID: 9662061
    [No Abstract]   [Full Text] [Related]  

  • 29. Lung peptidases, including carboxypeptidase, modulate airway reactivity to intravenous bradykinin.
    Chodimella V; Skidgel RA; Krowiak EJ; Murlas CG
    Am Rev Respir Dis; 1991 Oct; 144(4):869-74. PubMed ID: 1928964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and physiological role of angiotensin converting enzyme in rabbits lung.
    Yoshida N
    Jpn Circ J; 1979 Dec; 43 Suppl 1():9-10, 55-68. PubMed ID: 230370
    [No Abstract]   [Full Text] [Related]  

  • 31. Properties of the angiotensin-converting enzyme of lung.
    Cushman DW; Cheung HS; Peterson AE
    Chest; 1971 May; 59():Suppl:10S+. PubMed ID: 4325031
    [No Abstract]   [Full Text] [Related]  

  • 32. Angiotensin I converting enzyme of the lung.
    Igic R; Erdös EG; Yeh HS; Sorrells K; Nakajima T
    Circ Res; 1972 Sep; 31(9):Suppl 2:51-61. PubMed ID: 4341480
    [No Abstract]   [Full Text] [Related]  

  • 33. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
    Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin.
    Montenegro MF; Pessa LR; Tanus-Santos JE
    Eur J Pharmacol; 2009 Apr; 607(1-3):173-7. PubMed ID: 19233159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The release and fate of vaso-active hormones in the circulation.
    Vane JR
    Br J Pharmacol; 1969 Feb; 35(2):209-42. PubMed ID: 4388134
    [No Abstract]   [Full Text] [Related]  

  • 36. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme.
    Ferreira SH; Greene LH; Alabaster VA; Bakhle YS; Vane JR
    Nature; 1970 Jan; 225(5230):379-80. PubMed ID: 4312128
    [No Abstract]   [Full Text] [Related]  

  • 37. The inactivation of bradykinin in the pulmonary circulation of isolated lungs.
    Alabaster VA; Bakhle YS
    Br J Pharmacol; 1972 Jun; 45(2):299-310. PubMed ID: 4625922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Converting enzyme activity of free airway cells.
    Sirois P; Cadieux A
    Inflammation; 1986 Sep; 10(3):293-302. PubMed ID: 3017857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of bradykinin the plumonary circulation.
    Stewart JM
    Agents Actions; 1976 Jul; 6(4):494-7. PubMed ID: 961547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-identity between pulmonary bradykininase and converting-enzyme activity.
    Scholz HW; Biron P
    Rev Can Biol; 1969 Sep; 28(3):197-200. PubMed ID: 4310618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.